Travere Therapeutics(US:TVTX)2026-02-19 21:47Drug Approvals and Clinical Trials - FILSPARI (sparsentan) received full FDA approval on September 5, 2024, for slowing kidney function decline in adults with primary IgAN, following positive long-term results from the PROTECT Study[515]. - In the PROTECT Study, FILSPARI demonstrated a mean eGFR decline of -3.0 mL/min/1.73 m²/year compared to -4.2 mL/min/1.73 m²/year for irbesartan, indicating a statistically significant treatment effect of 1.2 mL/min/1.73 m²/year (p=0.0168)[517]. - FILSPARI has been granted seven years of Orphan Drug Exclusivity in the U.S. for both the reduction of proteinuria and slowing kidney function decline in adults with primary IgAN[520]. - The European Commission granted standard marketing authorization for FILSPARI in April 2025, leading to a regulatory milestone payment of $17.5 million received in May 2025[524]. - In the fourth quarter of 2025, FILSPARI generated a market access milestone payment of $40.0 million from CSL Vifor following its approval in the UK[524]. - The Phase 3 DUPLEX Study for sparsentan in FSGS showed a 42.0% partial remission of proteinuria at 36 weeks compared to 26.0% for irbesartan (p=0.0094)[529]. - The FDA accepted the sNDA for FILSPARI for FSGS treatment, with a PDUFA target action date of April 13, 2026, following a Major Amendment to the submission[531]. - Sparsentan has been granted Orphan Drug Designation for FSGS in the U.S. and the EEA, addressing a significant unmet need in this patient population[527]. - FILSPARI demonstrated a 67% to 77% lower risk of kidney failure for patients achieving partial or complete proteinuria remission in the DUPLEX Study[532]. - The pivotal Phase 3 HARMONY Study for pegtibatinase was initiated in December 2023 to support potential approval for treating classical HCU[538]. Financial Performance - Total revenue for the year ended December 31, 2025, was $490.7 million, a 110.5% increase from $233.2 million in 2024[568]. - Net product sales increased by $183.8 million to $410.5 million in 2025, primarily driven by growth in sales of FILSPARI[569]. - License and collaboration revenue rose by $73.8 million to $80.3 million, mainly due to market access and regulatory milestones totaling $57.5 million associated with CSL Vifor[570]. - Total operating expenses decreased slightly by $3.5 million to $553.6 million in 2025, with research and development expenses down by $11.5 million[571]. - Selling, general and administrative expenses increased by $73.1 million, attributed to higher intangible asset amortization and commercial investments for FILSPARI[580]. - Interest income decreased by $5.1 million to $12.7 million, while total other income, net, increased by $10.2 million to $13.6 million due to a gain on the sale of an equity investment[584]. - Cash provided by operating activities from continuing operations for the year ended December 31, 2025 was $37.8 million, a significant improvement from cash used of $230.0 million in 2024, driven by a $183.8 million increase in total net product sales and a $73.8 million increase in license and collaboration revenue[617]. - Cash provided by investing activities from continuing operations for the year ended December 31, 2025 was $27.9 million, down from $99.3 million in 2024, primarily due to decreased net proceeds from marketable debt securities and increased purchases of intangible assets[618]. - Cash used in financing activities from continuing operations for the year ended December 31, 2025 was $33.5 million, compared to cash provided of $139.4 million in 2024, influenced by a $68.9 million repayment of convertible notes and a prior issuance of common stock that generated $134.7 million in net proceeds[619]. Strategic Developments - The company entered an exclusive licensing agreement with Renalys Pharma for sparsentan in Japan and other Asian countries, with Renalys receiving Orphan Drug Designation in Japan[525]. - The company received an upfront cash payment of $210.0 million from Mirum Pharmaceuticals for the sale of its bile acid product portfolio[544]. - The company recognized a $226.0 million gain, net of tax, from the transaction related to the bile acid business as part of net income from discontinued operations[545]. - A strategic reorganization was implemented, resulting in an approximate 20% workforce reduction, expected to save about $25.0 million annually starting in 2024[546]. - The company has retained all rights to sparsentan in the United States and the rest of the world outside of the territories licensed to CSL Vifor and Chugai[534]. - The company is eligible to receive up to $235.0 million in milestone payments based on specified annual net sales of the bile acid products[544]. - The company expects to receive a milestone payment of $25.0 million in Q2 2026 from Mirum based on annual net sales achievements of its bile acid product portfolio, with potential total milestone payments of up to $235.0 million[592]. - The license agreement with CSL Vifor allows for up to $845.0 million in total potential payments, of which $57.5 million has been received as of December 31, 2025[593]. - The company has made a $65.0 million payment in Q2 2024 related to the acquisition of Orphan Technologies Limited, based on the achievement of a development milestone[609]. - The company is eligible for up to $120.0 million in milestone payments from the licensing agreement with Renalys Pharma, which came into effect in January 2024[596]. Cash and Financial Position - As of December 31, 2025, the company had cash and cash equivalents of $93.0 million, an increase from $58.5 million in 2024, and marketable debt securities valued at $229.8 million, down from $312.2 million in 2024[589]. - The accumulated deficit increased to $(1,472.7) million in 2025 from $(1,447.2) million in 2024, while stockholders' equity rose to $114.8 million from $59.1 million[589]. - As of December 31, 2025, the company had cash equivalents and marketable debt securities totaling approximately $322.8 million, with a potential $1.1 million impact from a 100 basis point change in interest rates[620]. - The company has not experienced material credit-related losses with its securities holdings due to its investment policy, which limits investments to high-quality instruments[621]. - The company is exposed to foreign currency exchange rate risk through contracts with vendors outside the U.S., but currently does not hedge this risk[622]. - Inflation has primarily impacted the company through increased labor costs, but has not affected its current outlook or business objectives[623]. Research and Development - The company has four Phase 3 clinical trials in process, with ongoing non-clinical support trials, indicating significant investment in clinical development[576]. - The company incurred a non-recurring $65.2 million charge in in-process research and development expense related to pegtibatinase in March 2024[581]. - The estimated addressable patient population for classical homocystinuria (HCU) is approximately 7,000 to 10,000 globally[535].